论文部分内容阅读
临床将40例联用多种口服降糖药血糖控制不理想的T_2DM患者随机分为甘精胰岛素联合瑞格列奈组(简称甘精组)和门冬胰岛素30组(简称门冬组)。甘精组每晚皮下注射甘精胰岛素,并于三餐前口服瑞格列奈,门冬组每日早晚餐前注射门冬胰岛素30,以FBG<7.2mmol/L、2h BG<10.0mmol/L为治疗目标,治疗12周。结果治疗前后两组的FBG、2hBG都明显下降,(P<0.01),两组间下降幅度比较,(P>0.05),血糖达标时的甘精组胰岛素用量少于门冬组,(P<0.01)。低血糖事件发生例数甘精组少于门冬组,差异有统计学意义(P<0.05)。结论甘精胰岛素联合瑞格列奈治疗能更有效控制血糖,低血糖发生率低,胰岛素用量小。
In the clinical trial, 40 patients with T 2 DM who were not controlled by many oral hypoglycemic agents were randomly divided into insulin glargine combined with repaglinide group and insulin aspart 30 group. Ganshen group was given insulin glargine subcutaneously every night, and repaglinide was given before three meals a day. Aspart 30 insulin was injected daily before and after meals as fasting time. FBG <7.2mmol / L, 2h BG <10.0mmol / L is the treatment target, for 12 weeks. Results Before and after treatment, the FBG and 2hBG levels of both groups were significantly decreased (P <0.01), and the decrease amplitude between the two groups was significantly lower (P> 0.05) <0.01). The incidence of hypoglycemic episodes in Gan Ganjing group was less than in winter group, the difference was statistically significant (P <0.05). Conclusion Glargine and repaglinide treatment can more effectively control blood sugar, low incidence of hypoglycemia, insulin dosage is small.